Hajnalka E. Davis

Statistics

Publications

Citations

170

H-Index

Active since

2011

Affiliations

AstraZeneca (United States)(Current)

Hajnalka E. Davis is an author at AstraZeneca (United States) specializing in antibiotic discovery, pharmacology, and novel antibacterial drug discovery.

Publications per year

2011–2015

Publications

Novel N-Linked Aminopiperidine Inhibitors of Bacterial Topoisomerase Type II: Broad-Spectrum Antibacterial Agents with Reduced hERG Activity

Folkert Reck, Richard A. Alm, Patrick Brassil et al. · Journal of Medicinal Chemistry · 2011 · 103 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

SAR and Structural Analysis of Siderophore-Conjugated Monocarbam Inhibitors of <i>Pseudomonas aeruginosa</i> PBP3

Kerry E. Murphy-Benenato, Brian Dangel, Hajnalka E. Davis et al. · ACS Medicinal Chemistry Letters · 2015 · 28 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Discovery of Efficacious <i>Pseudomonas aeruginosa</i>-Targeted Siderophore-Conjugated Monocarbams by Application of a Semi-mechanistic Pharmacokinetic/Pharmacodynamic Model

Kerry E. Murphy-Benenato, Pratik Bhagunde, April Chen et al. · Journal of Medicinal Chemistry · 2015 · 27 citations

Medicine, Medicinal Chemistry, Pharmacology +17

Identification through structure-based methods of a bacterial NAD+-dependent DNA ligase inhibitor that avoids known resistance mutations

Kerry E. Murphy-Benenato, Hongming Wang, Helen M. McGuire et al. · Bioorganic & Medicinal Chemistry Letters · 2013 · 12 citations · Full text

Life Sciences, Molecular Biology, Structural Bioinformatics +13

1–4 of 4